Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269903 | 0.82 | KIF11 (0.45) | KIF11KCNH2KMT2AKDM4EGAA | |
| SCHEMBL3269731 | 0.82 | KIF11 (0.45) | KIF11KCNH2KMT2AKDM4EGAA | |
| SCHEMBL3271216 | 0.78 | KIF11 (0.39) | KIF11KCNH2RAB9A | |
| SCHEMBL3269493 | 0.77 | KCNH2 (0.46) | KIF11KCNH2KDM4EGAA | |
| SCHEMBL3270268 | 0.77 | KCNH2 (0.46) | KIF11KCNH2KDM4EGAA | |
| SCHEMBL3271196 | 0.77 | KIF11 (0.58) | KIF11KCNH2KMT2AKDM4EGAA | |
| SCHEMBL3313395 | 0.76 | MTNR1A (0.36) | KIF11KCNH2KMT2ALMNAHTT | |
| SCHEMBL3268480 | 0.75 | KCNH2 (0.37) | KIF11KCNH2 | |
| SCHEMBL3275576 | 0.75 | KIF11 (0.47) | KIF11KCNH2 | |
| SCHEMBL3269665 | 0.74 | VKORC1 (0.39) | KIF11KCNH2KMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KMT2A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.